Novel T-Cell
Receptor Platform
Non-viral T-cell therapy
targeting solid tumors

Developing non-viral gene transfer-based cell therapies to effectively
access and treat the millions of people diagnosed globally each year with
solid tumors by weaponizing the body’s immune system.
Leveraging its multi-platform approach,
Ziopharm is at the forefront of immuno-oncology.

Sleeping Beauty T-Cell Therapy
Sleeping Beauty is one of the most clinically advanced non-viral cell therapy platforms that genetically modifies T cells to express tumor-targeting receptors, TCR. This technology enables a new, scalable approach to manufacturing cell therapy products. It has the potential to produce these therapies at a lower cost compared to what’s currently available.


Helping patients leverage the power of the immune system in the fight against cancer.